Castration-resistant prostate cancer: latest evidence and therapeutic implications.

ABSTRACT: Medical oncologists who treat men with castration-resistant prostate cancer (CRPC) have seen an abundance of new agents approved by the United States Food and Drug Administration in the last decade for a disease that was previously difficult to treat after becoming resistant to androgen-deprivation therapy. Advances in understanding of the mechanisms of castration-resistance and prostate cancer progression have highlighted several pathways and targets that appear promising to better treat CRPC. As the majority of CRPC appears to continue to rely on the androgen receptor for growth and progression, several of these agents directly or indirectly target the androgen receptor. A novel microtubule-targeted agent, cabazitaxel, has demonstrated an overall survival benefit following progression on

SUBMITTER: Suzman DL 

PROVIDER: S-EPMC4107711 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature